Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Glycerol rhizotomy and radiofrequency thermocoagulation for trigeminal neuralgia in multiple sclerosis.
MS and NMO: Partners No More.
Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon.
Motor impairments at presentation of clinically isolated syndrome suggestive of multiple sclerosis: Characterization of different disease subtypes.
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex.
Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.
Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.
Modulation of alertness by sustained cognitive demand in MS as surrogate measure of fatigue and fatigability.
Tocilizumab, MS, and NMOSD.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia.
Information on natalizumab (marketed as Tysabri)
Patients feeling severely affected by multiple sclerosis: How do patients want to communicate about end-of-life issues?
Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions.
Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Detection of inflammatory biomarkers in saliva and urine: Potential in diagnosis, prevention, and treatment for chronic diseases.
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.
Multiple sclerosis: Risk of comorbid inflammatory diseases in MS might not be genetically determined.
Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
PLEGRIDY™ (peginterferon beta-1a) approved in the European Union for the treatment of multiple sclerosis
Immune reconstitution inflammatory syndrome mimicking progressive multifocal leucoencephalopathy in a multiple sclerosis patient treated with natalizumab: a case report and review of the literature.

Pages